Fisher  &  Paykel  Healthcare   Corporation   Limited (NZSX:FPH, ASX:FPH) announced today that it has begun to introduce an extensive range of new respiratory interfaces to its international markets.

Fisher & Paykel Healthcare expects that the new interfaces will assist the company to expand the use of its respiratory care devices into a broader range of applications, with the potential to more than double the size of the market for its respiratory products.

The new interfaces have been developed for use across a variety of medical applications including non-invasive ventilation, oxygen therapy, humidity therapy and resuscitation.   The range of single patient use interfaces includes nasal and full face masks, tracheostomy and nasal oxygen therapy interfaces and neonatal resuscitation masks.

“We see a significant opportunity to supply additional innovative devices which can be used in the treatment of many more patients, both within and beyond our traditional intensive care ventilation market.   We believe that these new interfaces will assist us to more than double the respiratory patient population we can serve with our technology,” commented Michael Daniell, Fisher & Paykel Healthcare’s Chief Executive Officer.

The new interfaces have been introduced in New Zealand, Australia and selected international markets, with remaining markets to follow throughout the year.

About Fisher & Paykel Healthcare
Fisher   &  Paykel   Healthcare   is  a  leading   designer,   manufacturer   and  marketer   of  heated humidification  products  and systems  for use in respiratory  care and the treatment  of obstructive sleep apnea.  It also offers an innovative range of neonatal care products.  The company’s products are sold in over 90 countries worldwide.    For more information about the company visit www.fphcare.com.

Contact: Michael Daniell MD/CEO on +64 9 574 0161 or Tony Barclay CFO on +64 9 574 0119